![]() |
![]() |
Legal status
Patent in force
(51) | INT.CL. | C07D 519/00 | (2006.01) |
A61P 35/00 | (2006.01) | ||
A61K 47/68 | (2017.01) | ||
C07K 5/062 | (2006.01) |
(11) | Number of the document | 3612537 |
(13) | Kind of document | T |
(96) | European patent application number | 18718452.8 |
Date of filing the European patent application | 2018-04-18 | |
(97) | Date of publication of the European application | 2020-02-26 |
(45) | Date of publication and mention of the grant of the patent | 2022-07-13 |
(46) | Date of publication of the claims translation | 2022-10-10 |
(86) | Number | PCT/EP2018/059846 |
Date | 2018-04-18 |
(87) | Number | WO 2018/192944 |
Date | 2018-10-25 |
(30) | Number | Date | Country code |
201706133 | 2017-04-18 | GB | |
201721337 | 2017-12-19 | GB |
(72) |
HOWARD, Philip Wilson , GB
GREGSON, Stephen John , GB
|
(73) |
Medimmune Limited ,
Milstein Building
Granta Park, Cambridge, Cambridgeshire CB21 6GH,
GB
|
(74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
(54) | Pirolobenzodiazepino konjugatai |
PYRROLOBENZODIAZEPINE CONJUGATES |
Payment date | Validity (years) | Amount | |
2025-03-19 | 8 | 185.00 EUR |
2026-04-18 |